PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
36323780,Nociceptor neurons affect cancer immunosurveillance.,2022-11-01,Balood Mohammad; Ahmadi Maryam; Eichwald Tuany; Ahmadi Ali; Roversi Karine; Roversi Katiane; Huang Siyi; Ji Lexiang; Huang Kai-Chih; Semerena Elise; Thomas Sini C; Dai Hongyue; Shu Chengyi J; Rafei Moutih; Talbot Sebastien,partement de; Cygnal,sebastien.talbot@queensu.ca.
36198804,Author Correction: Glypican-1 identifies cancer exosomes and detects early pancreatic cancer.,2022-10-01,Fraga Mario F,National Center for,rkalluri@mdanderson.org.
14614483,Cancer robustness: tumour tactics.,2003-11-13,Kitano Hiroaki,Sony Computer Science Laboratories,None
39478232,Progressive plasticity during colorectal cancer metastasis.,2025-01-01,Benitez Elizabeth K; Cambulli Francesco; Jiang Qingwen; Mahmoud Ahmed; Lumish Melissa; Hartner Saskia; Balkaran Sasha; Bermeo Jonathan; Asawa Simran; Sgambati Valeria; Luckett Kathleen; Ganesh Karuna,Molecular,peerd@mskcc.org.
38778101,Selective haematological cancer eradication with preserved haematopoiesis.,2024-06-01,Lepore Rosalba; Camus Anna; Kirby Ian; Van Berkel Patrick H; Urlinger Stefanie,Cimeio; ADC,lukas.jeker@unibas.ch.
39743585,FBP1 controls liver cancer evolution from senescent MASH hepatocytes.,2025-01-01,Sauceda Consuelo; Gonzalez David J,Department of; Skaggs School of Pharmacy and,ligu@scu.edu.cn.
31578484,Harnessing innate immunity in cancer therapy.,2019-10-01,Demaria Olivier; Cornen Stéphanie; Morel Yannis; Vivier Eric,Innate,vivier@ciml.univ-mrs.fr.
39780006,Reinventing type 2 immunity in cancer.,2025-01-01,Wagner Marek,Life Sciences and,marek.wagner@port.lukasiewicz.gov.pl.
22895193,Recurrent R-spondin fusions in colon cancer.,2012-08-30,Seshagiri Somasekar,Genentech,sekar@gene.com
18754008,A paracrine requirement for hedgehog signalling in cancer.,2008-09-18,Yauch Robert L,Genentech,None
36517591,Recurrent repeat expansions in human cancer genomes.,2023-01-01,Dolzhenko Egor; Eberle Michael A,Illumina,gerwin@stanford.edu.
36385526,Ferroptosis of tumour neutrophils causes immune suppression in cancer.,2022-12-01,Sehgal Mohit,Intas,Dmitry.gabrilovich@astrazeneca.com.
39789339,Author Correction: Progressive plasticity during colorectal cancer metastasis.,2025-01-01,Benitez Elizabeth K; Cambuli Francesco; Jiang Qingwen; Mahmoud Ahmed; Lumish Melissa; Hartner Saskia; Balkaran Sasha; Bermeo Jonathan; Asawa Simran; Sgambati Valeria; Luckett Kathleen; Ganesh Karuna,Molecular,peerd@mskcc.org.
37380769,Reprogramming tumour-associated macrophages to outcompete cancer cells.,2023-07-01,Xu Ke,META,lim@mskcc.org.
39506152,Coordinated inheritance of extrachromosomal DNAs in cancer cells.,2024-11-01,Cravatt Benjamin F,Vividion,pmischel@stanford.edu.
31745371,Publisher Correction: Harnessing innate immunity in cancer therapy.,2019-12-01,Demaria Olivier; Cornen Stéphanie; Morel Yannis; Vivier Eric,Innate,vivier@ciml.univ-mrs.fr.
36634707,Targeting TBK1 to overcome resistance to cancer immunotherapy.,2023-03-01,Kim Jong Wook; Aref Amir R,Center for Novel,rjenkins@mgh.harvard.edu.
39890899,Author Correction: FBP1 controls liver cancer evolution from senescent MASH hepatocytes.,2025-02-01,Sauceda Consuelo; Gonzalez David J,Department of; Skaggs School of Pharmacy and,ligu@scu.edu.cn.
25901683,TP53 loss creates therapeutic vulnerability in colorectal cancer.,2015-04-30,Pahl Andreas; Anderl Jan,Heidelberg Pharma,None
37532929,Pharmacological targeting of netrin-1 inhibits EMT in cancer.,2023-08-01,Lengrand Justine; Bellina Melanie; Ducarouge Benjamin; Braissand Nicolas; Mehlen Patrick; Bernet Agnès,NETRIS,patrick.mehlen@lyon.unicancer.fr.
19935646,Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.,2009-12-10,Dang Lenny,Agios,None
37407818,Therapy-induced APOBEC3A drives evolution of persistent cancer cells.,2023-08-01,Maruvka Yosef E,Faculty of,hisozaki@mgh.harvard.edu.
37495687,Evolutionary histories of breast cancer and related clones.,2023-08-01,Saito Megumu,Otsuka,sogawa-tky@umin.ac.jp.
33981038,DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer.,2021-05-01,Poyurovsky Masha V; Olszewski Kellen,Kadmon Corporation,kellen@kadmon.com.
39633050,Evolution of myeloid-mediated immunotherapy resistance in prostate cancer.,2025-01-01,Lyu Aram; Miller Richard A; Fong Lawrence,Division of Translational Science and; Corvus,lawrence.fong@fredhutch.org.
28678784,Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.,2017-07-13,Sahin Ugur; Derhovanessian Evelyna; Miller Matthias; Kloke Björn-Philipp; Simon Petra; Bukur Valesca; Luxemburger Ulrich; Omokoko Tana; Vormehr Mathias; Paruzynski Anna; Kuhn Andreas N; Buck Janina; Heesch Sandra; Schreeb Katharina H; Müller Felicitas; Ortseifer Inga; Vogler Isabel; Godehardt Eva; Breitkreuz Andrea; Tolliver Claudia; Diekmann Jan; Ciesla Janko; Waksmann Olga; Brück Alexandra-Kemmer; Witt Meike; Zillgen Martina; Langer David; Bolte Stefanie; Diken Mustafa; Kreiter Sebastian; Huber Christoph,EUFETS,None
2462674,A novel cancer therapy using a Mössbauer-isotope compound.,,Mills R L,Mills Technologies,None
28658205,mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.,2017-07-06,Clasquin Michelle; Quang Phong; Murray Stuart; Barnett Amelia; Lein Gina; Pirman David; Marks Kevin; Marjon Katya,AGIOS,None
34433970,Author Correction: TP53 loss creates therapeutic vulnerability in colorectal cancer.,2021-09-01,Pahl Andreas; Anderl Jan,Heidelberg Pharma,xiongbinlu@gmail.com.
28321130,Effective combinatorial immunotherapy for castration-resistant prostate cancer.,2017-03-30,Zebala John A; Maeda Dean Y,Syntrix Biosystems,None
36922590,Spatial mapping of mitochondrial networks and bioenergetics in lung cancer.,2023-03-01,Xu Shili; Lee Jason T; Holloway Travis; Dubinett Steven M; Shirihai Orian S; Stiles Linsey,Department of Molecular and Medical,dshackelford@mednet.ucla.edu.
37612508,Non-cell-autonomous cancer progression from chromosomal instability.,2023-08-01,Tavora Bernardo; Havel Jonathan J; Bettigole Sarah,Volastra Therapeutics,ashley.laughney@gmail.com.
27193678,Reproducible pharmacogenomic profiling of cancer cell line panels.,2016-05-19,Haverty Peter M; Lin Eva; Tan Jenille; Yu Yihong; Lam Billy; Lianoglou Steve; Neve Richard M; Martin Scott; Settleman Jeff; Yauch Robert L; Bourgon Richard,Genentech,None
26416732,The genomic landscape of response to EGFR blockade in colorectal cancer.,2015-10-08,Diaz Luis A,The Ludwig Center for Cancer Genetics and,None
36352222,"Spatial genomics maps the structure, nature and evolution of cancer clones.",2022-11-01,Santagata Sandro,Laboratory of Systems,moritz.gerstung@dkfz.de.
34341547,Author Correction: DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer.,2021-08-01,Poyurovsky Masha V; Olszewski Kellen,Kadmon Corporation,kellen@kadmon.com.
25043045,Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.,2014-09-04,Yen Katharine E; Straley Kimberly S; Travins Jeremy; Popovici-Muller Janeta; Gliser Camelia,Agios,None
32238934,A genomic and epigenomic atlas of prostate cancer in Asian populations.,2020-04-01,Zhang Zhiming; Li Xiaoyun,Novogene Co,gaoxu.changhai@foxmail.com.
30405245,The metabolite BH4 controls T cell proliferation in autoimmunity and cancer.,2018-11-01,Talbot Sebastien,partement de,clifford.woolf@childrens.harvard.edu.
25079319,RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer.,2014-09-04,de Stanchina Elisa,Molecular,None
39048822,Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy.,2024-08-01,Salazar Andres M; Burns Robert; Costa Helio A; Moynihan Kelly D; Yeung Yik Andy; Djuretic Ivana,Oncovir; Natera,rdschreiber@wustl.edu.
39814891,IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer.,2025-02-01,Merghoub Taha,Department of,balachav@mskcc.org.
37258670,In situ tumour arrays reveal early environmental control of cancer immunity.,2023-06-01,Schöneberg Johannes,Department of,moussion.christine@gene.com.
28445469,Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.,2017-04-26,Constantin Tudor; Salari Raheleh; Kirkizlar Eser; Sponer Nicole; Hafez Dina; Naik Ashwini; Ganguly Apratim; Kareht Stephanie; Lin C Jimmy; Rabinowitz Matthew; Zimmermann Bernhard G,Natera,None
28489825,Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer.,2017-05-18,Fischer Marcus M; Cancilla Belinda; O'Young Gilbert; Cain Jennifer; Liu Yu-Wang; Kapoun Ann M; Hoey Timothy; Murriel Christopher L,OncoMed,None
37532934,Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer.,2023-08-01,Bellina Melanie; Ducarouge Benjamin; Lengrand Justine; Jelin Remy; Braissand Nicolas; Bernet Agnès; Mehlen Patrick,Netris,agnes.bernet@lyon.unicancer.fr.
29088702,Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition.,2017-11-09,Matov Alexandre,DataSet Analysis,None
20505728,The mutation spectrum revealed by paired genome sequences from a lung cancer patient.,2010-05-27,Lee William,Genentech,None
25428507,Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.,2014-11-27,Krebber Willem-Jan; Mulder Gwenn E,ISA,None
29059683,Association analysis identifies 65 new breast cancer risk loci.,2017-11-02,Loibl Sibylle,German Breast Group,None
27595393,On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models.,2016-11-03,Du Xinlin; Rizzi James P; Josey John A; Wallace Eli M,Peloton,None
21886163,Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.,2011-08-31,Breitbach Caroline J,Jennerex,None
31363232,Publisher Correction: The metabolite BH4 controls T cell proliferation in autoimmunity and cancer.,2019-08-01,Talbot Sebastien,partement de,clifford.woolf@childrens.harvard.edu.
32968282,Functional genomic landscape of cancer-intrinsic evasion of killing by T cells.,2020-10-01,Sousa Cristovão M; Fan Zi Peng; Krall Jordan A; Simons Donald M; Slater Chloe J; De Jesus Victor; Tang Lujia; Singh Richa; Goldford Joshua E; Martin Sarah; Smolen Gromoslaw A; Kingsbury Gillian A; Kung Charles,Agios; Celsius,j.moffat@utoronto.ca.
25470042,TRIM37 is a new histone H2A ubiquitin ligase and breast cancer oncoprotein.,2014-12-04,Tushir Jogender S,Boehringer Ingelheim,None
19360080,An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.,2009-04-09,Soucy Teresa A,Millennium,teresa.soucy@mpi.com
29364287,The biology and management of non-small cell lung cancer.,2018-01-24,Boshoff Chris,Pfizer,None
30305738,IRE1α-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity.,2018-10-01,Bettigole Sarah E; Shin Hee Rae,Quentis,laurie_glimcher@dfci.harvard.edu.
25428503,MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.,2014-11-27,Fine Gregg D; Teng Siew-leng; Shen Xiaodong; Boyd Zachary; Hegde Priti S; Chen Daniel S,Genentech,None
9872321,Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer.,1998-12-17,Pitti R M,Genentech,None
35197632,A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.,2022-03-01,Seung Edward; Wu Lan; Kirby Patrick; Wiederschain Dmitri; Wei Ronnie; Yang Zhi-Yong; Nabel Gary J,ModeX; Dragonfly; Jounce,Lily.Pao@sanofi.com.
27680702,XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.,2016-10-06,Landesman Yosef; Senapedis William; Baloglu Erkan,Karyopharm,None
24553136,The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.,2014-03-27,Choidas Axel; Schultz-Fademrecht Carsten; Eickhoff Jan; Menninger Sascha; Unger Anke; Klebl Bert M,Lead Discovery Center,None
25428504,Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.,2014-11-27,Kowanetz Marcin; Fine Gregg D; Rost Sandra; Leabman Maya; Xiao Yuanyuan; Mokatrin Ahmad; Koeppen Hartmut; Hegde Priti S; Mellman Ira; Chen Daniel S,Genentech,None
35332336,Publisher Correction: A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.,2022-04-01,Seung Edward; Wu Lan; Kirby Patrick; Wiederschain Dmitri; Wei Ronnie; Yang Zhi-Yong; Nabel Gary J,ModeX; Dragonfly; Jounce,Lily.Pao@sanofi.com.
24919154,Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.,2014-06-19,Hancox Timothy,Piramed,None
